Published online May 2, 2014. doi: 10.5314/wjd.v3.i2.15
Revised: January 13, 2014
Accepted: February 16, 2014
Published online: May 2, 2014
Core tip: Severity of psoriasis, a chronic, recurrent inflammatory disease, is clinically evaluated by Psoriasis Area and Severity Index that present some limitations and subjectivity. Biological markers for diagnosis and prognosis of psoriasis help to establish its severity and to monitor the therapeutic response; moreover, psoriasis biomarkers assist clinicians in their therapeutic decision to treat psoriasis and to choose earlier and more adequate therapeutic strategies, avoiding or minimizing psoriasis worsening. As any attempt to identify these biomarkers should be encouraged, in this review, we will debate published data concerning the proposal of biomarkers to evaluate severity and response to treatment of psoriasis.